Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Neuropsychiatric Impairments and Neurotransmitter-related Functional Alterations in Alzheimer’s Disease

Project description

Uncovering neuropsychiatric symptoms in Alzheimer’s disease

A significant proportion of individuals with Alzheimer’s disease (AD) suffer from neuropsychiatric symptoms (NPS) such as depression and agitation. These symptoms can appear before cognitive deficits and increase dementia risk significantly. With the support of the Marie Skłodowska-Curie Actions programme, the NINFA-AD project aims to study the neural changes linked to NPS in AD. The work will focus on neurotransmitter pathways and study how specific abnormalities contribute to NPS. The research team will combine functional MRI, PET imaging and cognitive data to uncover the underlying causes of NPS. Project findings are expected to improve diagnosis and care for individuals with AD.

Objective

Depressed mood, agitation, false beliefs, lack of motivation and other alterations in behaviour, usually named with the umbrella term of neuropsychiatric symptoms (NPS), are commonly observed in people with Alzheimers disease (AD). NPS are highly prevalent in people with AD (35-85%) and increase the risk of dementia by up to 10 times. The onset of NPS may even precede that of cognitive deficits and predict subsequent cognitive decline. Although not all patients experience NPS and some experience only very mild symptoms, clarifying AD aetiology is of primary importance to improve early diagnosis, provide better care and mitigate the economic burden of dementia. The neural changes associated with NPS in AD are still unclear and, consequently, wide consensus on the best treatment strategies is lacking. Since the earliest accumulation of AD pathology is observed in the nuclei involved in the production of neurotransmitters, the NINFA-AD project aims to investigate whether alterations in brain functioning influenced by abnormalities in different neurotransmitter pathways may be associated with NPS in people either with or at risk for AD. This aim will be pursued by applying an innovative interdisciplinary approach combining functional magnetic resonance with positron emission tomography imaging, fluid AD biomarkers and cognitive data. The NINFA-AD project will provide novel hypothesis-based insights on the cause of these symptoms that will lead to more efficient treatments and improvements in patients' prognosis. Moreover, the findings could be exploited to develop more informative biomarkers to be used in trials to test the mechanisms of action and effectiveness of novel interventions targeting behavioural problems in AD.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2023-PF-01

See all projects funded under this call

Coordinator

UNIVERSITA DEGLI STUDI DI PARMA
Net EU contribution
€ 172 750,08
Address
VIA UNIVERSITA 12
43121 PARMA
Italy
Region
Nord-Est Emilia-Romagna Parma
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Partners (1)